Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
NCT04732650 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2021-02-01
Summary
In this study, the investigator will evaluate the treatment effects and safety, patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan.
Conditions
- Eisenmenger Complex
Sponsors & Collaborators
- collaborator INDUSTRY
-
Samsung Medical Center
lead OTHER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-04
- Primary Completion
- 2023-12-31
- Completion
- 2024-12-31
More Related Trials
-
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
NCT00424021 ·Status: COMPLETED ·Phase: PHASE2
-
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
NCT06658522 ·Status: RECRUITING ·Phase: PHASE4
-
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
NCT01224210 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
NCT02545465 ·Status: COMPLETED
-
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
NCT05224531 ·Status: COMPLETED ·Phase: PHASE2
-
Bosentan in Treatment of Pulmonary Arterial Hypertension
NCT00266162 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
NCT07013149 ·Status: RECRUITING
-
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
NCT00317486 ·Status: COMPLETED ·Phase: PHASE4
-
Pulmonary Artery Remodelling With Bosentan
NCT00595049 ·Status: COMPLETED ·Phase: PHASE4
-
Real World Observational Study of Sotatercept for Pulmonary Hypertension
NCT06751082 ·Status: RECRUITING
-
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
NCT00120380 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
NCT01808313 ·Status: COMPLETED ·Phase: PHASE3
-
Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration
NCT01352065 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Bosentan and Pulmonary Endothelial Function
NCT01721564 ·Status: COMPLETED ·Phase: NA
-
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
NCT00879229 ·Status: TERMINATED ·Phase: PHASE3
-
Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia
NCT01449253 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
NCT01054105 ·Status: COMPLETED
-
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT01178073 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
NCT01338636 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacogenomics in Pulmonary Arterial Hypertension
NCT00593905 ·Status: WITHDRAWN
-
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
NCT03738150 ·Status: COMPLETED ·Phase: PHASE2
-
Simvastatin as a Treatment for Pulmonary Hypertension
NCT00180713 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
NCT04811092 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Ambrisentan in Participants With Pulmonary Hypertension
NCT00777920 ·Status: COMPLETED ·Phase: PHASE3
-
Upfront Combination Pulmonary Arterial Hypertension Therapy
NCT03809156 ·Status: UNKNOWN ·Phase: PHASE4